NCT07027163

A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis

Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis - A Multicenter Retrospective Analysis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 62 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 6 Years
• Healthy volunteers: Not accepted

Summary

This was a retrospective, multi-center observational study conducted across four allergy departments in Europe (Berlin, Leipzig, Barcelona, and Basel). The study included patients with immunoglobulin E (IgE)-mediated food allergy who were treated with omalizumab, either as monotherapy or in combination with oral immunotherapy (OIT) between 2002-2022.

Conditions

• Food Hypersensitivity
• Anaphylaxis

Timeline

• Start date: 2023-06-01
• Primary completion: 2023-09-01
• Completion: 2023-09-01
• First posted: 2025-06-18
• Last updated: 2025-06-18

Locations

1 site across 1 country: United States